Dash Bio Raises $30M Series A to Accelerate Drug Development Timelines
Dash Bio, the company building the infrastructure that drug development needs for the next generation of medicines, today announced it has raised $30 million in Series A financing. The round was led by Oak HC/FT, with participation from existing investors, including Freestyle Capital and Swift Ventures.
